Linked Life Data

11461950

Source:http://linkedlifedata.com/resource/pubmed/id/11461950

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11461950rdf:typepubmed:Citationlld:pubmed
pubmed-article:11461950lifeskim:mentionsumls-concept:C0010825lld:lifeskim
pubmed-article:11461950lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:11461950lifeskim:mentionsumls-concept:C0022671lld:lifeskim
pubmed-article:11461950lifeskim:mentionsumls-concept:C0209368lld:lifeskim
pubmed-article:11461950lifeskim:mentionsumls-concept:C0021149lld:lifeskim
pubmed-article:11461950lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:11461950lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:11461950lifeskim:mentionsumls-concept:C1167870lld:lifeskim
pubmed-article:11461950pubmed:issue8lld:pubmed
pubmed-article:11461950pubmed:dateCreated2001-7-19lld:pubmed
pubmed-article:11461950pubmed:abstractTextGanciclovir, which is used to treat cytomegalovirus (CMV) infection, has been shown in rodent models to abolish CMV-mediated chronic cellular damage and endothelial cell proliferation; when associated with mycophenolate mofetil (MMF), it has been shown to increase its anti-herpes virus activity. This study tested the hypothesis that kidney graft recipients who received antirejection prophylaxis with MMF and who were treated with ganciclovir for a declared CMV disease could be protected from chronic graft dysfunction. Investigated was the impact of ganciclovir-treated CMV diseases in consecutive first kidney recipients according to their immunosuppressive therapy. The azathioprine (Aza)-treated group (Aza group) included 319 patients. The MMF-treated group (MMF group) included 126 patients. CMV disease was clinically defined and confirmed by virological proof of CMV infection and was treated for at least 14 d with ganciclovir. Despite having the same incidence (21.6% in the Aza group versus 24.6% in the MMF group) and severity, CMV disease was significantly associated with graft loss independent of acute rejection episodes or other factors when tested in a Cox proportional model in the Aza group only (P < 10(-4)). It was shown for the first time that patients whose CMV disease is treated with ganciclovir while they are on MMF therapy are protected from the long-term deleterious consequences of CMV disease on graft survival, independent of acute rejection. It is suggested that the enhanced anti-herpes virus activity of ganciclovir by MMF could contribute to this reported effect, which may represent a significant contribution of MMF efficacy to graft survival.lld:pubmed
pubmed-article:11461950pubmed:languageenglld:pubmed
pubmed-article:11461950pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11461950pubmed:citationSubsetIMlld:pubmed
pubmed-article:11461950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11461950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11461950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11461950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11461950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11461950pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11461950pubmed:statusMEDLINElld:pubmed
pubmed-article:11461950pubmed:monthAuglld:pubmed
pubmed-article:11461950pubmed:issn1046-6673lld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:SoulillouJ...lld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:HourmantMMlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:DantalJJlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:GiralMMlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:BlanchoGGlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:JosienRRlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:CantarovichDDlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:NguyenJ MJMlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:AnceletDDlld:pubmed
pubmed-article:11461950pubmed:authorpubmed-author:DaguinPPlld:pubmed
pubmed-article:11461950pubmed:issnTypePrintlld:pubmed
pubmed-article:11461950pubmed:volume12lld:pubmed
pubmed-article:11461950pubmed:ownerNLMlld:pubmed
pubmed-article:11461950pubmed:authorsCompleteYlld:pubmed
pubmed-article:11461950pubmed:pagination1758-63lld:pubmed
pubmed-article:11461950pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:meshHeadingpubmed-meshheading:11461950...lld:pubmed
pubmed-article:11461950pubmed:year2001lld:pubmed
pubmed-article:11461950pubmed:articleTitleMycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction.lld:pubmed
pubmed-article:11461950pubmed:affiliationInstitut de Transplantation et de Recherche en Transplantation (ITERT) and INSERM U437, 30 Boulevard Jean Monnet, 44093 Nantes Cedex 1, France.lld:pubmed
pubmed-article:11461950pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11461950lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11461950lld:pubmed